Drugs / Olea europaea pollen extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02849210 | Sep 2015 → Jun 2017 | allergic rhinitis | Roxall Medicina España S.A | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olea europaea pollen extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02849210 ↗ |
| Route | Subcutaneous | “Subcutaneous immunotherapy in depot presentation” NCT02849210 ↗ |